NICE green lights Roche’s Rozlytrek for NTRK tumoursThe UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid Share XNICE green lights Roche’s Rozlytrek for NTRK tumourshttps://pharmaphorum.com/news/nice-green-lights-roches-rozlytrek-for-ntrk-tumours/
Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from BayerThe UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the Share XTumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayerhttps://pharmaphorum.com/news/tumour-agnostic-drugs-game-changing-says-nice-as-it-rejects-one-from-bayer/
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EUBayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy for cancer based on Share XBayer’s Vitrakvi is first tumour-agnostic drug approved in EUhttps://pharmaphorum.com/news/bayers-vitrakvi-is-first-tumour-agnostic-drug-approved-in-eu/
